News Sentiment

COGT sentiment intelligence

Cogent Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.08 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+0.5% over one week, +13.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

COGT6232219 Bond Coupon Profile — Rate & Payments

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive 13.1% over four weeks
Fair value 155.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 40
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
TradingView 9
Stock Titan 5
GlobeNewswire 5
simplywall.st 4
Sahm 3
Moomoo 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 15
Balance sheet 2
Analyst action 2
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
TradingView Direct company coverage

COGT6232219 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Cogent Biosciences, Inc. bond COGT6232219, which has a 1.625% interest rate maturing on November 15, 2031. It details the current coupon rate of 1.63% and announces that the next payment is scheduled for November 16, 2026. The page o

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 19:11
Source
TradingView
TradingView Direct company coverage

COGT6232219 Bond Profile — Key Metrics

This article provides key metrics and an overview of the COGT6232219 bond issued by Cogent Biosciences, Inc. It details the bond's coupon rate, maturity date, issue date, outstanding amount, and face value. Additionally, it offers a brief description of Cogent Biosciences, Inc. a

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 05:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT

This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its Price to Sales forward metric. The content highlights that market data is provided by ICE Data Services and FactSet, and SEC filings are by Quartr.

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 00:09
Source
TradingView
Stock Traders Daily Direct company coverage

(COGT) Movement Within Algorithmic Entry Frameworks

The article provides an algorithmic analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting strong sentiment across all time horizons and an exceptional risk-reward short setup. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—wit

Tone
Positive 74/100
Event
Market update
Published
11 Jul 2026 17:08
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to EBITDA forward of Cogent Biosciences, Inc. – NASDAQ:COGT

This article provides financial data specifically on the enterprise value to EBITDA forward for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a stub or data-focused page from a financial charting and analysis platform, presenting this specific metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 18:39
Source
TradingView
Sahm Direct company coverage

Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation

Cogent Biosciences has filed a New Drug Application (NDA) with the FDA for bezuclastinib, targeting Advanced Systemic Mastocytosis, following positive trial results. Despite strong recent share price performance, the company's valuation, at a 12.8x Price-to-Book ratio, is conside

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 14:10
Source
Sahm
Sahm Direct company coverage

Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)?

Cogent Biosciences has submitted a New Drug Application to the FDA for bezuclastinib, supported by strong data from the APEX trial showing disease modification in advanced systemic mastocytosis. This filing, coupled with ongoing Expanded Access Programs, is a significant catalyst

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 03:04
Source
Sahm
TradingView Direct company coverage

Price to book forward of Cogent Biosciences, Inc. – NASDAQ:COGT

This article provides financial data for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its forward price-to-book ratio. It is a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. The page includes

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 14:45
Source
TradingView
Stock Titan Direct company coverage

Cogent Biosciences (COGT) director takes options in lieu of cash

Cogent Biosciences director Karen Jean Ferrante received a grant of 627 stock options on July 1, 2026, as compensation instead of cash fees. These options have an exercise price of $38.48 per share and expire on July 1, 2036. This grant was part of the company's non-employee dire

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jul 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Cogent Biosciences, Inc. – NASDAQ:COGT

This article provides forward-looking enterprise value to revenue data for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a financial data point from TradingView, offering a snapshot of a specific valuation metric. The content is very brief and seems to be a data eleme

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 13:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cogent Biosciences, Inc. – NASDAQ:COGT

This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT) focusing on its price to earnings forward. It is presented in a data-centric format from TradingView, including market data and reference data from various financial service providers.

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 03:09
Source
TradingView
Sahm Direct company coverage

3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing

Cogent Biosciences (COGT) filed a New Drug Application with the FDA for bezuclastinib, leading to a significant rally in its share price. Despite strong performance and positive trial data, the stock appears pricey with a price-to-book ratio of 12.1x, significantly above the broa

Tone
Negative 39/100
Event
Market update
Published
03 Jul 2026 12:09
Source
Sahm
Finviz Direct company coverage

COGT - Cogent Biosciences Inc Forecast, Target Price

This article provides a detailed financial overview and forecast for Cogent Biosciences Inc (COGT). It includes key metrics such as market capitalization, income, sales, P/E ratios, and various performance indicators. The data also presents analyst recommendations and a target pr

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 21:40
Source
Finviz
GuruFocus Direct company coverage

Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib

Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib, a treatment for Advanced Systemic Mastocytosis, supported by APEX clinical trial findings. Despite this milestone, the company faces challenges indicated by its low GF Score™ of 25/100 and

Tone
Negative 37/100
Event
Market update
Published
30 Jun 2026 22:41
Source
GuruFocus
Stock Traders Daily Direct company coverage

How (COGT) Movements Inform Risk Allocation Models

This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) using AI models, indicating a strong overweight bias across all time horizons. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analy

Tone
Positive 63/100
Event
Market update
Published
30 Jun 2026 16:00
Source
Stock Traders Daily
Stock Titan Direct company coverage

Cogent seeks FDA approval for rare blood disease drug

Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for its drug bezuclastinib, targeting advanced systemic mastocytosis (AdvSM). This submission is supported by positive data from the APEX pivotal trial, which showed high objective response rates and a well-

Tone
Positive 79/100
Event
Regulatory and legal
Published
30 Jun 2026 12:09
Source
Stock Titan
GlobeNewswire Direct company coverage

Cogent Biosciences Announces Submission of New Drug

Cogent Biosciences has submitted a New Drug Application (NDA) to the FDA for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), based on positive data from the APEX pivotal trial. The company expects the drug to receive its first approvals later in 2026, building on s

Tone
Positive 73/100
Event
Guidance
Published
30 Jun 2026 12:09
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base

Cogent Biosciences (COGT) saw its stock rise 6.7% after its removal from several Russell indices, including the Russell 3000E and Russell 2000 Value. This removal is expected to reshape the company's investor base by shifting out passive institutional money, potentially impacting

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:09
Source
Simply Wall Street
marketscreener.com Direct company coverage

Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index

Cogent Biosciences, Inc. (NasdaqGS:COGT) has been removed from the Russell Microcap Value Benchmark Index. This news follows several other announcements regarding the company's exclusion from various Russell indices on June 29th and 28th, 2026. Despite these index changes, the co

Tone
Negative 39/100
Event
Market update
Published
29 Jun 2026 22:09
Source
marketscreener.com
TradingView Direct company coverage

COGT Forecast — Price Target — Prediction for 2027

This article provides a forecast for Cogent Biosciences, Inc. (COGT) stock, including analyst price targets, historical performance, and financial data. Analysts have a 1-year price forecast, with a max estimate of $72.00 and a min estimate of $35.00. The company's stock has seen

Tone
Positive 72/100
Event
Analyst action
Published
26 Jun 2026 20:41
Source
TradingView
TradingView Direct company coverage

Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT)

This article provides current stock performance data and financial estimates for Cogent Biosciences, Inc. (COGT). It covers recent stock price movements, analyst forecasts, historical highs and lows, market capitalization, and upcoming earnings reports, along with financial metri

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 19:24
Source
TradingView
Insider Monkey Direct company coverage

Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress

Cogent Biosciences Inc. (NASDAQ: COGT) presented promising preclinical data for its novel JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. This candidate, designed to be a best-in-class therapy, shows high selectivity and oral bioavailability, aiming to treat myeloprolife

Tone
Positive 74/100
Event
Market update
Published
24 Jun 2026 14:10
Source
Insider Monkey